Back

Managing a patient with residual risk: applying recent evidence with EPA to practice

31 August 2024 (15:30 - 15:40)
Organised by: Logo
Congress Presentation Part of: Clinical scenarios addressing residual risk in atherosclerotic cardiovascular disease (ASCVD): understanding the role of triglycerides and eicosapentaenoic acid (EPA) Risk Factors and Prevention Open Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Introduction; a clinical case of a patient with ASCVD and high triglyceride levels
Professor P. Steg (Paris, FR)
Presentation thumbnail
Understanding the role of triglycerides in the assessment of residual risk
Professor A. Zambon (Padua, IT)
Presentation thumbnail
Integrating EPA in CV risk reduction strategies: practical experience and guidance
Professor A. Zaman (Newcastle-Upon-Tyne, GB)
Presentation thumbnail
Discussion: 5 burning questions from the audience
Slides Video
Presentation thumbnail
The 5 key take home messages
Slides Video

Access the full session

Session thumbnail
Clinical scenarios addressing residual risk in atherosclerotic cardiovascular disease (ASCVD): understanding the role of triglycerides and eicosapentaenoic acid (EPA)

The Event

Event poster

ESC Congress 2024

31 August 2024 15:30 CET
You may be interested in
thumbnail
Congress Session
Clinical scenarios addressing residual risk in atherosclerotic cardiovascular disease (ASCVD): understanding the role of triglycerides and eicosapentaenoic acid (EPA)
thumbnail
Congress Presentation
Understanding the clinical benefit of icosapent ethyl: insights from REDUCE-IT
thumbnail
Congress Session
Addressing residual cardiovascular risk: from evidence to experience

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources